Yes, Polio Vaccination Remains Part of Routine Immunization in the United States
All children in the United States should receive four doses of inactivated poliovirus vaccine (IPV) at ages 2 months, 4 months, 6-18 months, and 4-6 years as part of routine immunization. 1, 2
Current U.S. Polio Vaccination Policy
The United States has exclusively used IPV for routine immunization since January 1,2000, when oral poliovirus vaccine (OPV) was completely phased out. 1 This policy change was implemented specifically to eliminate vaccine-associated paralytic poliomyelitis (VAPP), a rare but serious complication that occurred with OPV use at a rate of approximately 1 case per 2.9 million OPV doses distributed. 3
Routine Childhood Schedule
The standard IPV series consists of:
- Dose 1: 2 months of age
- Dose 2: 4 months of age
- Dose 3: 6-18 months of age
- Dose 4: 4-6 years of age (booster dose)
The final dose must be administered at age ≥4 years regardless of the number of previous doses. 1 If the third dose is given on or after the fourth birthday, a fourth dose is not needed. 4
Minimum Intervals Between Doses
- Doses 1 to 2 and doses 2 to 3: minimum 4 weeks apart
- Dose 3 to dose 4: minimum 6 months apart (extended from the previous 4-week minimum in 2009) 1
- Minimum age for first dose: 6 weeks 1
Important caveat: Using minimum age and minimum intervals in the first 6 months of life should only occur if the infant is at risk for imminent poliovirus exposure (e.g., during an outbreak or travel to endemic regions), as shorter intervals lead to lower seroconversion rates. 1
Adult Vaccination Recommendations
Routine poliovirus vaccination of adults (≥18 years) residing in the United States is generally not necessary, as most adults have minimal risk for poliovirus exposure and are already immune from childhood vaccination. 4
Adults Who Should Receive IPV
However, as of 2023, ACIP now recommends that all U.S. adults aged ≥18 years who are known or suspected to be unvaccinated or incompletely vaccinated complete a primary polio vaccination series with IPV. 5 This updated recommendation followed the 2022 detection of vaccine-derived poliovirus type 2 causing paralytic polio in an unvaccinated young adult in New York, with subsequent evidence of community transmission. 5
Adults at increased risk who definitely need vaccination include:
- Travelers to regions where polio is endemic or epidemic
- Healthcare workers with close contact to patients potentially excreting polioviruses
- Laboratory workers handling specimens that may contain polioviruses
- Members of communities with disease caused by wild polioviruses 4, 6
Adult Primary Series
Unvaccinated adults should receive:
- Three doses of IPV: First two doses 4-8 weeks apart, third dose 6-12 months after the second 4
- Adults who completed a primary series and are at increased risk can receive a one-time lifetime booster dose 4, 7
Most adults born and raised in the United States can assume they were vaccinated against polio as children. 7
Safety Profile
IPV has an excellent safety record. Since expanded use began in 1996, no serious adverse events have been linked to IPV use in the United States. 4 The Institute of Medicine found no serious adverse events associated with IPV in countries using all-IPV schedules. 4
The only contraindication is severe allergic (anaphylactic) reaction to a previous IPV dose or to streptomycin, polymyxin B, or neomycin (trace amounts present in the vaccine). 4, 6
Why IPV Continues Despite U.S. Being Polio-Free
Although the last case of indigenously acquired wild poliovirus in the United States occurred in 1979 3, vaccination continues because:
- Wild poliovirus type 1 and vaccine-derived polioviruses still circulate globally 5
- Risk of importation remains real, as demonstrated by the 2022 New York case 5
- Unvaccinated populations can sustain transmission if poliovirus is imported 8
- IPV provides excellent protection with 99-100% seroconversion rates after the complete series 6
The 2024 immunization schedule confirms IPV remains a core component of routine childhood vaccination in the United States. 2